Authorization is based on the results from three Phase 3 multicenter, randomized, double-blind, placebo-controlled registrational clinical trials evaluating the efficacy and safety or RINVOQ in monotherapy or in combination with topical corticosteroids. 1 RINVOQ demonstrated improvements in skin clearance and itch reduction compared to placebo. Milestone marks the third Health Canada-approved indication for RINVOQ ...
  • Authorization is based on the results from three Phase 3 multicenter, randomized, double-blind, placebo-controlled registrational clinical trials evaluating the efficacy and safety or RINVOQ (upadacitinib) in monotherapy or in combination with topical corticosteroids. 1
  • RINVOQ demonstrated improvements in skin clearance and itch reduction compared to placebo.
  • Milestone marks the third Health Canada-approved indication for RINVOQ 1†

ABBVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved RINVOQ ® (upadacitinib), an oral, once-daily selective JAK inhibitor for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis (AD) who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. RINVOQ ® can be used with or without topical corticosteroids.

Atopic dermatitis (AD) is characterized by intense uncontrolled itching, dry skin, which becomes cracked, hardened, oozing and painful.  It is estimated that up to 17% of Canadians will suffer from AD at some points in their lives. 2

"Atopic dermatitis is a chronic inflammatory skin disease that impacts both patients and caregivers. As atopic dermatitis is common at all ages, it affects many Canadians. I have seen first-hand the debilitating impact of atopic dermatitis on patients through my research and my practice," states Dr. Kim Alexander Papp , MD, PhD, FRCPC, Probity Medical Research and K. Papp Clinical Research, Waterloo ON. "If we hope to improve patients' overall quality of life, clinicians need more tools.  Having access to advanced therapies allows us to better support patients and provide them with treatment outcomes that address their unmet needs."

The Health Canada authorization is supported by data from a large registrational Phase 3 clinical trial program in atopic dermatitis including more than 2,500 adults and adolescents with moderate to severe disease. 1 These multicenter, randomized, double-blind, placebo-controlled registrational clinical trials evaluated the efficacy and safety of RINVOQ monotherapy (Measure Up 1 [MU1] and Measure Up 2 [MU2]) and with topical corticosteroids (AD Up [AU]) compared to placebo. 1 3 4 In all three studies, the co-primary endpoints were at least a 75 percent improvement in the Eczema Area and Severity Index (EASI 75) and validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0/1 (clear or almost clear) at week 16. 1 3 4

Eczema Society of Canada's Executive Director Amanda Cresswell-Melville highlights the burden of atopic dermatitis. "The impacts of atopic dermatitis on quality of life for both patients and caregivers are often underestimated and misunderstood," says Cresswell-Melville. "Patients may be seeking additional options to address their unmet needs in the management of their condition.  New treatment options bring hope to these patients."

Chronic inflammatory skin diseases go well beyond the surface and affect both physical and mental health. The exact cause of atopic dermatitis is unknown, but a combination of immune, genetic, and environmental factors is believed to be involved. 3

"AbbVie is dedicated to the pursuit of innovation in life sciences and advancing the standards of care for patients," says Tracey Ramsay , Vice President and General Manager, AbbVie Canada.  "We are proud of our strong heritage in dermatology and continue to deepen our understanding of the complex nature of serious inflammatory skin conditions. Through this milestone in atopic dermatitis, we remain committed to developing and delivering leading-edge therapies for patients who need them most."

About RINVOQ® (upadacitinib)

RINVOQ is a once-daily oral medication in an extended-release tablet. It is a Janus kinase (JAK) inhibitor that interferes with the JAK-STAT signaling pathway, which is thought to play a role in inflammatory response.

RINVOQ is indicated for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis (AD) who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable. RINVOQ can be used with or without topical corticosteroids.

For therapeutic and important safety information, please consult the RINVOQ Product Monograph at www.abbvie.ca .

About AbbVie in Dermatology

For more than a decade, AbbVie has worked to uncover new solutions and improve care for people with serious skin diseases.  With a broad clinical trial program, we continue to actively research and adapt to the evolving needs of the dermatology community and advance our pipeline to help people achieve their treatment goals and live beyond their skin disease.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca .  Follow @abbviecanada on Twitter or find us on LinkedIn.

1 RINVOQ (upadacitinib) Product Monograph. AbbVie Corporation. Available at https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ_PM_EN.pdf.

2 Canadian Dermatology Association. Eczema https://dermatology.ca/public-patients/skin/eczema/

3 Guttman-Yassky E., et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290): 2151-2168. doi:10.1016/S0140-6736(21)00588-2.

4 Reich K, Teixeira HD, Bruin-Weller, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10290): 2169-2181.

5 Eczema Society of Canada. What is eczema? https://eczemahelp.ca/about-eczema/

RINVOQ ® is registered trademark of AbbVie Corporation.

SOURCE Allergan, an AbbVie Company

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2021/07/c1091.html

News Provided by Canada Newswire via QuoteMedia

Bristol Myers 48 Hour Deadline Alert: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits against Bristol-Myers Squibb Company - BMY

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE:BMY), if they received Contingent Value Rights ("CVRs") in exchange for their shares of Celgene Corporation pursuant to BMS' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York

What You May Do

Keep reading... Show less

Cohen Milstein Files Class Action Complaint Against Bristol-Myers Squibb Company

Cohen Milstein Sellers & Toll PLLC ("Cohen Milstein") today announced that its ongoing investigation has led to the filing of a class action complaint against Bristol-Myers Squibb Company ("Bristol Myers") and several of its senior executives and directors. The case was filed in the United States District Court for the Southern District of New York, Case No. 21-cv-10351

The action was brought on behalf of all former Celgene Corporation ("Celgene") (CELG) shareholders that received Contingent Value Rights ("CVRs") in exchange for their Celgene shares pursuant to Bristol Myers' $74 billion acquisition of Celgene on November 20, 2019, and were damaged thereby, and all persons who purchased CVRs between November 20, 2019 and December 31, 2020 (the "Class Period"), and who were damaged thereby (the "Class").

Keep reading... Show less

BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York.

What You May Do

Keep reading... Show less

AbbVie Provides Update on RINVOQ® for the Treatment of Rheumatoid Arthritis in the U.S.

ABBVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ ® (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). This update follows a Drug Safety Communication (DSC) issued on Sept. 1, 2021 by the U.S. Food and Drug Administration (FDA) following its final review of the post-marketing study, ORAL Surveillance, evaluating XELJANZ ® (tofacitinib) in patients with RA. 1 The results of this study showed a higher rate of major adverse cardiac events (MACE), malignancy, mortality and thrombosis in XELJANZ (a Janus kinase (JAK) inhibitor) versus TNF blockers. 1 The DSC and this label update apply to the class of systemically administered FDA-approved JAKs indicated for the treatment of RA and other inflammatory diseases. 1

Based on this class-wide update, the U.S. label for RINVOQ will now include additional information about the risks of malignancy and thrombosis, and the addition of mortality and MACE (defined as cardiovascular death, myocardial infarction and stroke) risks within the Boxed Warnings and Warnings and Precautions sections. 1 The indication has also been updated to the following: RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. 1

Keep reading... Show less

Amgen Announces 10% Increase In 2022 First Quarter Dividend

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022 to all stockholders of record as of the close of business on February 15, 2022 . This represents a 10% increase from that paid in each of the previous four quarters.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Keep reading... Show less

U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® in Adults with Non-Transfusion Dependent Beta Thalassemia

Submission based on results from Phase 2 BEYOND study of Reblozyl plus best supportive care in adults with NTD beta thalassemia

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl ® (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 27, 2022. In addition, the European Medicines Agency has validated the Type II variation for Reblozyl in NTD beta thalassemia. Reblozyl is being co-developed and co-commercialized with Merck & Co., Inc., known as MSD outside the United States and Canada, following Merck's recent acquisition of Acceleron Pharma, Inc.

Keep reading... Show less

Top News

Related News